Hyun Ah Yoon
<div id="cit_full" class="meta">
<p class="j"> </p>
</div>
<div class="ab"> </div>
<div id="cit_full" class="meta">
<p class="j"> </p>
</div>
<div class="ab"> </div>
<p>Dr. Weston’s research interests include the epidemiology, mechanisms of resistance, and therapy of multi-drug resistant gram-negative infections, particularly Carbapenem-Resistant Enterobateriaceae. He works with mathematical modeling techniques to predict which patients are at high risk of CRE bloodstream infections. He also organizes Montefiore’s participation in the CRACKLE II multicenter database of CRE infections.</p>
<p>Dr. Weston’s inpatient clinical work is on a service dedicated to infectious disease consultation in the intensive care and step down units of Weiler hospital. This includes brief daily rounds with each unit to identify needs for consultation and provide antibiotic stewardship guidance. He is a member of the Montefiore Antibiotic Stewardship Team and also sees patients in an Outpatient Parenteral Antibiotic Therapy clinic.</p>
<p>Dr. Weston is a graduate of Regis High School in New York. He received his undergraduate education summa cum laude from the College of the Holy Cross in Worcester, Massachusetts. He received a medical degree from the College of Physicians and Surgeons of Columbia University in New York. He completed Internal Medicine residency at the Emory University School of Medicine in Atlanta, Georgia. Dr. Weston joined Montefiore Medical Center and the Albert Einstein College of Medicine in 2013 for his fellowship in Infectious Diseases. During Fellowship he completed a Master’s of Science in Clinical Research degree in the Einstein Clinical Research Training Program. </p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/28167547">Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.</a> Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, Seo SK, Rosenthal ME, Sperber SJ, Jenkins SG, Hamula CL, Uhlemann AC, Levi MH, Fries BC, Tang YW, Juretschko S, Rojtman AD, Hong T, Mathema B, Jacobs MR, Walsh TJ, Bonomo RA, Kreiswirth BN. <em>Antimicrobial Agents and Chemotherapy</em> 2017; 61: e02349-16</p>
<p>A multicenter study measuring appropriateness of carbapenem use. Weston G, Jacob JT, Ray S, Varkey J, Gaynes RP. Infection Control and Hospital Epidemiology 2013; 34: 1324-1326</p>
<p><em><span style="text-decoration: underline;">Toxoplasma gondii</span></em>, microsporidiosis, stage differentiation, polar tube structure and function</p>
<p><strong>Toxoplasmosis:</strong> <em>Toxoplasma gondii</em> is a ubiquitous Apicomplexan protozoan parasite that infects humans, mammals and birds. Despite recent progress in understanding the biology of the rapidly replicating form (tachyzoite), very little is known about the cyst form (bradyzoite). The bradyzoite stage plays a critical role in maintenance of latent infection, the relapse of infections and the development of chronic neurologcial disease. Our research is focused on the identification of cyst wall (bradyzoite) proteins and how they function. </p>
<p><strong>Microsporidiosis:</strong> The phylum Microspora consists of organisms collectively known as microsporidia, that are "emerging" human and veterinary pathogens. A microsporidian-specific organelle, the polar tube, is involved in invasion. While the description of the polar tube as a unique microsporidian structure occurred over 100 years ago, the biochemical components of this structure and the mechanism of its formation during invasion remain to be definitively determined. The laboratory is focused on projects invovling the: (1) characterization of the structure and composition of the polar tube and spore wall, and (2) the identificiation of therapeutic targets for the treatment of microsporidiosis. </p>
Treatment and diagnosis of infectious diseases, with a focus on parasitology and global health.
Investigates the biology of Toxoplasma gondii and its ability to cause latent infections, with a focus on the composition and structure of the T. gondii tissue cyst.
<p>Mayoral J, Guevara RB, Rivera-Cuevas Y, Tu V, Tomita T, Romano JD, Gunther-Cummins L, Sidoli S, Coppens I, Carruthers VB, Weiss LM. Dense Granule Protein GRA64 interacts with host cell ESCRT proteins during <em>Toxoplasma gondii</em> infection.mBio. 2022 Jun 22:e0144222. doi: 10.1128/mbio.01442-22.</p>
<p>Tomita T, Mukhopadhyay D, Han B, Yakubu R, Tu V, Mayoral J, Sugi T, Ma Y, Saeij JPJ, Weiss LM. <em>Toxoplasma gondii</em> matrix antigen 1 is a secreted immunomodulatory effector. mBio. 2021 May 18;12(3):e00603-21. </p>
<p>Flores J, Takvorian PM, Weiss LM, Cali A, Gao N. Human microsporidian pathogen <em>Encephalitozoon intestinalis</em> impinges on enterocyte membrane trafficking and signaling. J Cell Sci. 2021 Feb 15:jcs.253757. doi: 10.1242/jcs.253757.</p>
<p>Mayoral J, Tomita T, Tu V, Aguilan JT, Sidoli S, Weiss LM. <em>Toxoplasma gondii</em> PPM3C, a secreted protein phosphatase, affects parasitophorous vacuole effector export. PLoS Pathog. 2020 Dec 28;16(12):e1008771. doi: 10.1371/journal.ppat.1008771. </p>
<p>Mayoral J, Shamamian P Jr, Weiss LM. In Vitro Characterization of protein effector export in the bradyzoite stage of Toxoplasma gondii. mBio. 2020 Mar 10;11(2). pii: e00046-20. doi: 10.1128/mBio.00046-20. PMID: 32156805</p>
<p><span lang="EN">Tu V, Tomita T, Sugi T, Mayoral J, Han B, Yakubu RR, Williams T, Horta A, Ma Y, Weiss LM. The <em>Toxoplasma gondii</em> cyst wall interactome. mBio. 2020 Feb 4;11(1). pii: e02699-19. doi: 10.1128/mBio.02699-19.PMID: 32019789</span></p>
<p>Tu V, Mayoral J, Yakubu RR, Tomita T, Sugi T, Han B, Williams T, Ma Y, Weiss LM.MAG2, a <em>Toxoplasma gondii</em> bradyzoite stage-specific cyst matrix protein. mSphere. 2020 Feb 19;5(1). pii: e00100-20. doi:10.1128/mSphere.00100-20.PMID: 32075884</p>
<p><span lang="EN">Han B, Ma Y, Tu V, Tomita T, Mayoral J, Williams T, Horta A, Huang H, Weiss LM Microsporidia interact with host cell mitochondria via voltage-dependent anion channels using sporoplasm Surface Protein 1. mBio. 2019 Aug 20;10(4). pii: e01944-19. doi: 10.1128/mBio.01944-19. PMID: 31431557</span> <span lang="EN">PMC6703431</span></p>
<p><span lang="EN">Takvorian PM, Han B, Cali A, Rice WJ, Gunther L, Macaluso F, Weiss LM. An ultrastructural study of the extruded polar tube of<em> Anncaliia algerae</em> (Microsporidia). J Eukaryot Microbiol. 2019 Jul 22. doi: 10.1111/jeu.12751. PMID: 31332877</span></p>
<p><span lang="EN">Tomita T, Wang H, Wu P, Weiss LM.Stage-specific and selective delivery of caged azidosugars into the intracellular parasite <em>Toxoplasma gondii</em> by using an esterase-ester pair technique. mSphere. 2019 May 29;4(3). pii: e00142-19. doi: 10.1128/mSphere.00142-19. PMID: 31142619</span></p>
<p>Tu V, Mayoral J, Sugi T, Tomita T, Han B, Ma YF, Weiss LM. Enrichment and proteomic characterization of the cyst wall from in vitro <em>Toxoplasma gondii</em> cysts. mBio. 2019 Apr 30;10(2). pii: e00469-19. doi: 10.1128/mBio.00469-19. PMID: 31040239</p>
<p>Sugi T, Tu V, Ma Y, Tomita T, Weiss LM. <em>Toxoplasma gondii</em> requires glycogen phosphorylase for balancing amylopectin storage and for efficient production of brain cysts. mBio. 2017 Aug 29;8(4). pii: e01289-17. doi: 10.1128/mBio.01289-17.PMID: 28851850 PMC5574715</p>
<p>Yakubu RR, Silmon de Monerri NC, Nieves E, Kim K, Weiss LM. Comparative Monomethylarginine proteomics suggests that protein arginine methyltransferase 1 (PRMT1) is a significant contributor to arginine monomethylation in <em>Toxoplasma gondii</em>. Mol Cell Proteomics. 2017 Apr;16(4):567-580. doi: 10.1074/mcp.M117.066951. Epub 2017 Jan 31.PMID: 28143887</p>
<p>Han B, Polonais V, Sugi T, Yakubu R, Takvorian PM, Cali A, Maier K, Long M, Levy M, Tanowitz HB, Pan G, Delbac F, Zhou Z, Weiss LM. The role of microsporidian polar tube protein 4 (PTP4) in host cell infection. PLoS Pathog. 2017 Apr 20;13(4):e1006341. doi: 10.1371/journal.ppat.1006341. eCollection 2017 Apr. PMID: 28426751</p>
<p>Sugi T, Ma YF, Tomita T, Murakoshi F, Eaton MS, Yakubu R, Han B, Tu V, Kato K, Kawazu S, Gupta N, Suvorova ES, White MW, Kim K, Weiss LM. Toxoplasma gondii cyclic AMP-dependent protein kinase subunit 3 is involved in the switch from tachyzoite to bradyzoite development. mBio. 2016 May 31;7(3). pii: e00755-16. doi: 10.1128/mBio.00755-16. PMID: 27247232 PMCID: PMC4895117</p>
<p>El Bissati K, Suvorova ES, Xiao H, Lucas O, Upadhya R, Yan Fen Ma YF, Hogue Angeletti R, White MW, Weiss LM, Kim K <em>Toxoplasma gondii</em> arginine methyltransferase 1 (PRMT1) regulates centrosome dynamics during tachyzoite cell division. mBio. 2016 Feb 2;7(1):e02094-15. doi: 10.1128/mBio.02094-15. PMID: 26838719 PMCID: PMC4742710</p>
<p>Silmon de Monerri NC, Yakubu RR, Chen AL, Bradley PJ, Nieves E, Weiss LM, Kim K. The Ubiquitin proteome of <em>Toxoplasma gondi</em>i reveals roles for protein ubiquitination in cell-cycle transitions. Cell Host Microbe. 2015 Nov 11;18(5):621-33. doi: 10.1016/j.chom.2015.10.014. PMID: 26567513</p>
<p>Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, Kim K, Weiss LM.The <em>Toxoplasma gondii</em> cyst wall protein CST1 is critical for cyst wall integrity and promotes bradyzoite persistence. PLoS Pathog. 2013 Dec;9(12):e1003823. doi: 10.1371/journal.ppat.1003823. PMID:24385904</p>
<p>Morada M, Lee S, Gunther-Cummins L, Weiss LM, Widmer G, Tzipori S, Yarlett N. Continuous culture of <em>Cryptosporidium parvum</em> using hollow fiber technology. Int J Parasitol. 2015 Sep 2. pii: S0020-7519(15)00220-9. doi: 10.1016/j.ijpara.2015.07.006. PMID: 26341006</p>
<p>Ma Y, Weiss LM, Huang H. Inducible suicide vector systems for <em>Trypanosoma cruzi</em>. Microbes Infect. 2015 Jun;17(6):440-50. doi: 10.1016/j.micinf.2015.04.003. Epub 2015 Apr 18. PMID: 25899945</p>
<p>Nardelli SC, Che FY, Silmon de Monerri NC, Xiao H, Nieves E, Madrid-Aliste C, Angel SO, Sullivan WJ Jr, Angeletti RH, Kim K, Weiss LM. The Histone Code of <em>Toxoplasma gondii</em> Comprises Conserved and Unique Posttranslational Modifications. mBio. 2013 Dec 10;4(6). doi:pii: e00922-13. 10.1128/mBio.00922-13. PMID:24327343</p>
<p>Pombert JF,Selman M,Burki F,Bardell FT,Farinelli L,Solter LF,Whitman DW,Weiss LM, Corradi N, Keeling PJ. Gain and loss of multiple functionally related, horizontally transferred genes in the reduced genomes of two microsporidian parasites. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12638-43. Epub 2012 Jul 16. PMID:22802648</p>
<p>Ghosh K, Nieves E, Keeling P, CaliA, Weiss LM. A new vesicular compartment in <em>Encephalitozoon cuniculi</em>. Microbes Infect. 2012 Apr;14(4):324-8. PMID:22166342</p>
<p>Ghosh K, Nieves E, Keeling P, Pombert JF, CaliA, Weiss LM. A branching network of proteinaceous filaments within the parasitophorous vacuole of<em> Encephalitozoon cuniculi</em> and <em>Encephalitozoon hellem</em>. Infect Immun. 2011 Jan 10. PMID: 21220485</p>
<p>Bouzahzah B, Nagajyothi F, Ghosh K, Takvorian PM, CaliA, Tanowitz HB, Weiss LM. Interactions of <em>Encephalitozoon cuniculi</em> polar tube proteins. Infect Immun. 2010 Jun;78(6):2745-53. Epub 2010 Mar 22. PMID: 20308291</p>
<p>Alvarado JJ, Nemkal A, Sauder JM, Russell M, Akiyoshi DE, Shi W, Almo SC, Weiss LM. Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470. Mol Biochem Parasitol. 2009 Aug 4. PMID: 19660503</p>
<p><strong>BOOKS</strong></p>
<p>Weiss LM and Kim K (eds.) <em>Toxoplasma gondii</em> the model Apicomplexan: Methods and Applications, Elsevier Press (Academic Press), 3rd edition, 2020.</p>
<p>Weiss LM and Reinke AW (eds.) Microsporidia: Current Advances in Biology, Springer, 2022.</p>
<p>Weiss LM and Becnel JJ (eds.) Microsporidia: Pathogens of Opportunity, Wiley-Blackwell, 2014.</p>
<p>Louis M. Weiss, MD, MPH, is Vice Chair, Academic Affairs and Research, Pathology, Co-Director, Einstein Global Health Center and Professor, Pathology and Medicine (Infectious Diseases) at Montefiore Einstein. His clinical expertise is in the treatment and diagnosis of infectious diseases, with a focus on parasitology and global health.</p><p>After obtaining his Bachelor of Arts in biology and chemistry from Lehigh University in 1978, Dr. Weiss earned his Doctor of Medicine and Master of Public Health at Johns Hopkins University in 1982. Following this, Dr. Weiss completed his internship and residency in medicine at the University of Chicago in 1985 and an infectious diseases fellowship at Einstein Montefiore in 1989.</p><p>Dr. Weiss investigates the biology of <em>Toxoplasma gondii</em> and its ability to cause latent infections, with a focus on the composition and structure of the <em>T. gondii</em> tissue cyst. He also investigates the biology of infection due to the microsporidia, with a focus on the composition of the polar tube and how it functions during microsporidian invasion of a host cell. His research has been published in numerous peer-reviewed journals, articles, books and chapters, and he has presented this research both nationally and internationally. Dr. Weiss has been a reviewer for scientific journals including <em>mBIO</em>, the <em>Journal of Eukaryotic Microbiology</em>, the <em>American Journal of Tropical Medicine and Hygiene, PLOS Pathogens</em>, the <em>Journal of Infectious Diseases</em> and <em>Experimental Parasitology</em>, and is an editor for <em>mBIO</em> and <em>Microbes and Infection</em>.</p><p>Dr. Weiss is board certified in Internal Medicine and Infectious Diseases. He is a Fellow of the Infectious Diseases Society of America, the American College of Physicians and the American Academy of Microbiology of the American Society of Microbiology. In 2000, Dr. Weiss was inducted into the Leo M. Davidoff Society for his outstanding teaching of medical students.</p>
<p>Dr. Torres completed his MD degree at Universidad del Valle (Cali, Colombia) in 2006. He then joined the International Center for Training and Medical Research (CIDEIM) in his home town, Cali, where he spent almost 3 years as a research assistant in the area of Gram negative Bacterial Resistance, where he published and presented his work in national and international journals and conferences.</p>
<p>After completing his Internal Medicine residency at Jacobi Medical Center in the Bronx, Dr. Torres completed his fellowship in Infectious Diseases at New York University (NYU). He then joined Englewood Hospital where he spent more than 2 years as an Infectious Disease consultant.</p>
<p>Dr. Torres joined Montefiore Medical Center/Albert Einstein College of Medicine in 2017 as an Assistant Professor. Since then, he has been providing PrEP, PEP, STI, HCV and HIV care to patients in the Bronx, as well as inpatient Infectious Disease consultation services at the hospital. He has an interest to expand HIV prevention projects in Colombia and is working closely with Corporacion de Lucha contra el SIDA in Cali.</p>
<p>Dr. Torres has been a member of the Infectious Disease Society of America since 2012.</p>
<p> </p>
<p> </p>
<p align="left"><strong><span style="font-family: Times New Roman; font-size: medium;">Selected Publications</span></strong><strong><span style="text-decoration: underline;"><span style="font-family: Times New Roman; font-size: medium;"><br /></span></span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Nori P, Szymczak W, Puius J, Sharma A, Cowman K, Fleischner Z, Bartash R, Chen V, Corpuz M, Gialanella P, Alpert P, Felsen U,<strong> Torres-Isasiga J</strong>, Guo Y. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;">Int J Antimicrob Agents. 56(6):106179. doi: 10.1016/j.ijantimicag.2020.106179. Epub 2020 Sep 25.<strong> (2020)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Mueses-Marín HF, Alvarado-Llano B, </span><strong style="mso-bidi-font-weight: normal;"><span lang="ES" style="color: black; mso-color-alt: windowtext;">Torres-Isasiga J</span></strong><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">, Camargo-Plazas P, Bolívar-Rocha MC, Galindo-Orrego X, Martínez-Cajas JL. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Scales to Assess Knowledge, Motivation, and Self-Efficacy for HIV PrEP in Colombian MSM: PrEP-COL Study. AIDS Research and Treatment, vol. 2021, Article ID 4789971, 11 pages </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2021)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Falsey AR, et al., </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">and the AstraZeneca AZD1222 Clinical Study Group (Julian A. Torres). </span></strong><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://pubmed.ncbi.nlm.nih.gov/34587382/"><span lang="EN-US" style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; text-decoration: none; text-underline: none;">Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine</span></a></span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">. </span><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">N Engl J Med. </span><span lang="ES" style="font-size: 10.5pt; font-family: 'Segoe UI',sans-serif; color: #4d8055; background: white;"> </span><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">doi: 10.1056/NEJMoa21052902021. </span><strong style="mso-bidi-font-weight: normal;"><span lang="ES" style="color: black; mso-color-alt: windowtext;">(2021).</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Martínez-Cajas J, Alvarado-Llano B, Martínez-Buitrago E, <strong>Torres-Isasiga J</strong>, Arrivillaga M, Camargo P, Galindo-Orrego X, Mueses-Marín H. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://pubmed.ncbi.nlm.nih.gov/35067114/"><span lang="EN-US" style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; text-decoration: none; text-underline: none;">AC-2020-12-1420.R1 - HIV care providers' familiarity, concerns, and attitudes about HIV PrEP in Colombia: insights from the PrEP-Col-Study.</span></a></span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"> AIDS Care. doi: 10.1080/09540121.2022.2029813 </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2022)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Martínez-Cajas JL, <strong>Torres J, </strong>Mueses HF, Camargo Plazas P, Arrivillaga M, Gomez SA, Galindo X, Martínez Buitrago E, Alvarado-Llano BE. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Applying Implementation Science Frameworks to Identify Factors that Influence the Intention of Healthcare Providers to Offer PrEP Care and Advocate for PrEP in HIV Clinics in Colombia: A Cross-Sectional Study. Implement Sci Commun. Mar 16; 3(1):31. doi.org/10.1186/s43058-022-00278-2 </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2022)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">Meyerowitz EA, Bernardo, RM, Collins-Ogle, MD, Mamber Czeresnia, J, Morales Matos, C, Mullis C, Root, H; <strong>Torres-Isasiga JA</strong>, Tsai, H; Zingman, B. Navigating HIV Screening Recommendations for People on PrEP and the Need to Update Testing Algorithms. </span><em><span lang="ES" style="color: black; mso-color-alt: windowtext;">Open Forum Infectious Diseases</span></em><span lang="ES" style="color: black; mso-color-alt: windowtext;">, ofac191. <a href="https://doi.org/10.1093/ofid/ofac191"><span style="color: black; mso-color-alt: windowtext; text-decoration: none; text-underline: none;">doi.org/10.1093/ofid/ofac191</span></a> <strong>(2022)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO;">Arrivillaga M, Gómez SA, Mueses HF, Alvarado B, Martínez Buitrago E, Camargo-Plazas P, Hurtado LR, Bolívar MC, Galindo X, <strong>Torres J</strong>, Cajas-Martínez JL. Facilitadores y recomendaciones de proveedores de salud para la implementación de la Profilaxis Pre-Exposición en clínicas de VIH en Colombia. “Estudio PPrE-Colombia”. Rev Gerenc Polit Salud;21. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.o…; target="_blank" rel="noopener"><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO; text-decoration: none; text-underline: none;">https://doi.org/10.11144/Javeriana.rgps21.frps</span></a></span><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO;"> <strong>(2022)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: 0.5in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><!-- [if !supportLists]--><span lang="ES-CO" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: ES-CO;">·<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><!--[endif]--><span lang="ES-CO">Meyerowitz EA, Gendlina I, Desai VJ, Grossberg R, Nair SR, Pujar B, Riska PF, Root HB, Toro J, <strong>Torres JA</strong>, Pirofski LA, Zingman BS. Anorectal Testing for Monkeypox Virus Infection in Men who have Sex with Men with and without Proctitis. Clin Infect Dis. 2022 Oct 13:ciac825. doi: 10.1093/cid/ciac825. Epub ahead of print. PMID: 36227656 <strong>(2022)</strong></span></p>
<p>Julian A. Torres lsasiga, MD, is an attending physician at Montefiore Einstein and Associate Professor, Infectious Diseases at our Albert Einstein College of Medicine. Dr. Torres’s clinical focus centers on general infectious disease care, HIV prevention and care, sexually transmitted infections and medical education.</p><p>After earning his Doctor of Medicine at the Universidad del Valle/Hospital Universitario del Valle in Cali, Colombia in 2006, Dr. Torres became a research assistant at the International Center for Medical Research and Training (CIDEIM) in Cali, Colombia, from 2007 to 2009. He then moved to the United States to continue his medical training, completing his internal medicine residency at Jacobi Medical Center in 2012 and an infectious disease fellowship at New York University in 2014.</p><p>Building on his clinical focus, Dr. Torres’s research is focused on HIV prevention and pre-exposure prophylaxis (PrEP). He has been co-investigator, principal investigator and sub-investigator on several research projects and he has shared his work through many national and international invited presentations and poster presentations. Dr. Torres is a reviewer for <em>Clinical Infectious Disease, Open Forum Infectious Disease</em> and the <em>International Journal of STD & AIDS</em>. His work has been published in numerous peer-reviewed journals, books, chapters, review articles and abstracts.</p><p>Dr. Torres is board certified in Internal Medicine and Infectious Disease by the American Board of Internal Medicine. He is a member of the Infectious Disease Society of America. In 2023, he received the Excellence in Teaching Award from the Division of Infectious Disease at Montefiore Einstein. The same year, Dr. Torres received the Teaching Star-Teaching Commendation Letter for the 2022-2023 Academic Year from Montefiore Einstein.</p>
Kidney stones, Glomerular diseases, Chronic kidney disease, End Stage renal disease
Treatment for anemia in patients with chronic kidney disease and end stage renal disease on dialysis
<p></p>Deep Sharma, MBBS, earned his medical degree from University College of Medical Sciences in Delhi, India. He then completed his residency and chief residency at Good Samaritan Hospital, Baltimore followed by his nephrology fellowship at Montefiore Medical Center where he joined as faculty after completion of his fellowship. He is board certified in Medicine and Nephrology and is a member of the American Society of Nephrology. Dr. Sharma is the clinical director of Nephrology for Weiler Hospital and the medical director of Fresenius Eastchester and Fresenius Freedom Center of the Bronx that treats patients who need dialysis for End Stage Kidney disease, both incenter and at home. With the help of his Urology colleagues, he helped establish the kidney stone program at Montefiore and that sees patients with kidneys stones in the clinic. Dr. Sharma has been involved in clinical studies looking at muscle mass in patients with kidney disease and the treatment of anemia in patients with chronic kidney disease and dialysis.<p></p>
<p class="p1"> </p>
<p class="p1">The major focus of research in the Ross laboratory is to identify novel mechanisms of kidney injury occurring in HIV-positive persons and his laboratory uses in vitro and murine models to generate new strategies to prevent and treat kidney diseases. Dr. Ross also works with members of the International Network for Strategic Initiatives in Global HIV Treatment (INSIGHT) to perform research on kidney disease in the context of large international HIV treatment trials.</p>
<p class="p1"><strong><span style="text-decoration: underline;">Ongoing NIH-funded projects:</span></strong></p>
<p class="p1"><strong>Mechanisms by which antiretroviral medications protect kidneys from HIV-induced injury:</strong></p>
<p class="p1">Though combination antiretroviral therapy (cART) is efficacious in preventing and treating HIV-associated nephropathy (HIVAN), the mechanisms by which these medications protect the kidney from the deleterious effects of HIV are poorly understood. We are performing studies using transgenic animal models and molecular and genomic techniques to identify novel pathways by which ART protect the kidneys from HIV. Moreover, we have exciting data suggesting that these medications may protect kidneys from non-viral mediated forms of kidney injury, including diabetic kidney disease.</p>
<p class="p1"><strong>The role of APOL1 polymorphisms in promoting HIV-induced kidney injury:</strong></p>
<p class="p1">Polymorphisms in the APOL1 gene account for most of the excess risk of African-Americans to non-diabetic kidney disease and HIV-associated kidney disease in particular. In our studies, we are using genetically modified human kidney cells to perform innovative proteomic, and genomic studies to identify novel mechanisms by APOL1 genetic variants predispose to HIV-induced kidney injury. </p>
<p><span style="color:black;">Chronic kidney disease, diabetic kidney disease, acute kidney injury, glomerular diseases, cystic kidney diseases, electrolyte disorders, hypertension, HIV and other virus-related kidney diseases.</span></p>
<p><span style="color:black;">The primary focus of Dr. Ross' research is to identify mechanisms by which HIV and immune dysregulation cause kidney disease and to identify new approaches to prevent and treat kidney disease. Dr. Ross is also involved in clinical studies to determine mechanisms of diabetic kidney injury and to test the effectiveness of novel treatments for chronic kidney diseases.</span></p>
<p><span style="text-decoration: underline;"><strong>Most relevant publicatiion in past 10 years:</strong></span></p>
<p>*Mocroft, A., Wyatt, C., Szczech, L., Neuhaus, J., El-Sadr, W., Tracy, R., Kuller, L., Shlipak, M., Angus, B., Klinker, H., and <strong><span style="text-decoration: underline;">Ross, MJ</span></strong>. Interruption of antiretroviral therapy is associated with increased plasma cystatin C: Results from the SMART Study. <em>AIDS</em>. 23, 71-82. 2009.</p>
<p>*Snyder A, Alsauskas Z, Gong P, Rosenstiel P, Klotman M, Klotman P, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>: FAT10: a novel mediator of Vpr-induced apoptosis in HIV-associated nephropathy. <em>J Virol</em>. 83;11983-11988. 2009.</p>
<p>*Gong, P., Canaan, A., Wang, B., Leventhal, S., Snyder, A., Nair, V., Cohen, C. D., Kretzler, M., D'Agati, V., Weissman, S., and <strong><span style="text-decoration: underline;">Ross, M. J</span></strong>. The ubiquitin-like protein FAT10 mediates NF-kappaB activation. J Am Soc Nephrol. 21:316. 2009.</p>
<p>Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, Chan J, Barley K, He C, Klotman M, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Klotman PE. HIV-1 viral protein r induces ERK and caspase-8 dependent apoptosis in renal tubular epithelial cells. <em>AIDS</em>, 24:1107-1119. 2010.</p>
<p>Neuhaus, J., Jacobs, D.R., Baker, J.V., Calmy, A., Duprez, D., La Rosa, A., Kuller, L., Pett, S.L., Ristola, M., <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong>, Shlipak, M., Tracy, R., and Neaton, J.D. Markers of Inflammation, Coagulation and Renal Function Are Elevated in Adults with HIV Infection. <em>J Infect Dis</em>. 201:1788-1795. 2010.</p>
<p>Chen, P., Chen, B.K., Mosoian, A., Hays, T., <strong><span style="text-decoration: underline;">Ross, M.J</span></strong>., Klotman, P.E., and Klotman, M.E. Virological Synapses Allow HIV-1 Uptake and Gene Expression in Renal Tubular Epithelial Cells. J Am Soc Nephrol. 22(3): 496-507. 2011.</p>
<p>Leventhal, J.S., Alsauskas, Z., Snyder, A., Gong, P., Wang, B., D’Agati, V., and <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong> Renal HIV Expression Is Unaffected by Serum LPS Levels in an HIV Transgenic Mouse Model of LPS Induced Kidney Injury. <em>PLoS One.</em> <strong>6</strong>:e20688. 2011.</p>
<p>Papeta, N., Kiryluk, K., Patel, A., Sterken, R., Kacak, N., Snyder, H.J., Imus, P.H., Mhatre, A.N., Lawani, A.K., Julian, B.A., Wyatt, R.J., Novak, J., Wyatt, C.M., <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong>, Winston, J.A., Klotman, M.E., Cohen, D.J., Appel, G.B., D’Agati, V.D., Klotman, P.E., and Gharavi, A.G. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. <em>J Am Soc Nephrol.</em> 22:1991-1996. 2011.</p>
<p>Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, Szymczak A, Lundgren J, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>*, Wyatt CM*: Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. PLoS ONE 7:e40245, (*co-senior authors). 2012.</p>
<p>Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD: Exposure to Antiretrovirals (ARVs) and Risk of Renal Impairment among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. J Infect Dis 2013.</p>
<p>Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, Okulicz JF, Landrum M, Agan B, Whitman TJ, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Crum-Cianflone NF: Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV Med 14:65-76, 2013</p>
<p>Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 1;207(9):1359-69. 2013.</p>
<p>Lucas, G., Cozzi-Lepri, A., Wyatt, C., Post, F., Bormann, A., Crum-Cianflone, N., and <strong><span style="text-decoration: underline;">Ross, M</span></strong>. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med 15:116-123. PubMed PMID: 24024499. 2014.</p>
<p>Lucas, GM, <strong><span style="text-decoration: underline;">Ross, MJ</span></strong>, Stock, PG, Shlipak, MG, Wyatt, CM, Gupta, SK, Atta, MG, Wools-Kaloustian, KK, Pham, PA, Bruggeman, LA, Lennox, JL, Ray, PE, and Kalayjian, RC. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update By the HIV Medicine Association of the Infectious Diseases Society of America. <em>Clin Infect Dis</em>; 59(9), e96-e138. 2014.</p>
<p>Ryom, L., Mocroft, A., Kirk, O., <strong><span style="text-decoration: underline;">Ross, M</span></strong>., Reiss, P., Fux, C. A., Morlat, P., Moranne, O., Smith, C., El-Sadr, W., Law, M., and Lundgren, J. D. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 28, 187-199. 2014.</p>
<p>Mocroft A, Lundgren J, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Heuhaus J, Fux C, Moranne O, Morlat P, Johnson M, Ryom L; Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT study group. A clinically useful risk-score for chronic kidney disease in HIV infection. J Int AIDS Soc ;17(4 Suppl 3):19514.. PMID: 25394023; PMCID: PMC4224906. 2014.</p>
<p>Leventhal, J.S., He, J.C., and <strong><span style="text-decoration: underline;">Ross, M.J</span></strong><span style="text-decoration: underline;">.</span> Autophagy and Immune Response in Kidneys. <em>Semin Nephrol.</em> 34(1):53-61. 2014.</p>
<p><strong><span style="text-decoration: underline;">Ross, M. J.</span></strong> (2014). Advances in the pathogenesis of HIV-associated kidney diseases. <em>Kidney Int.</em> 86, 266-274. 2014.</p>
<p>Mocroft A, Lundgren JD, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809. PMID: 25826420; PMCID: PMC4380415. 2015.</p>
<p>Wolf T, <strong><span style="text-decoration: underline;">Ross MJ*</span></strong>, and Davenport A. Minimizing risks associated with renal replacement therapy in patients with Ebola Virus Disease. <em>Kidney Int.</em> 2015. 87, 5-7. 2015.</p>
<p>Achhra AC, Mocroft A, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Ryom L, Lucas GM, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell JM, Wyatt CM; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med;16 Suppl 1:55-63. PMID: 25711324; PMCID: PMC4341947. 2015.</p>
<p>Mocroft A, Lundgren JD, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 3:e23-32. 2016.</p>
<p>Leventhal JS, Ni J, Osmond M, Lee K, Gusella GL, Salem F, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. Autophagy Limits Endotoxemic Acute Kidney Injury and Alters Renal Tubular Epithelial Cell Cytokine Expression. PLoS One. 11(3):e0150001. 2016.</p>
<p>Ryom, L, Lundgren, JD, <strong><span style="text-decoration: underline;">Ross, M</span></strong>, Kirk, O, Law, M, Morlat, P, Smit, C, Fontas, E, Fux, CA, Hatleberg, CI, de Wit, S, Sabin, CA, Mocroft, A, D:A:D, SG. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. J Infect Dis. PMID: 27485357. 2016.</p>
<p>Ryom L, Mocroft A, Kirk O, Reiss P, <strong><span style="text-decoration: underline;">Ross M,</span></strong> Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD; D:A:D study group.. Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals. AIDS. 2017 Mar 28. PMID: 28353536.</p>
<p>Nadkarni GN, Wyatt CM, Murphy B, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. APOL1: a case in point for replacing race with genetics. Kidney Int. 2017 Apr;91(4):768-770. PMID: 28314574.</p>
<p>Rednor SJ, <strong>Ross MJ</strong>. Molecular Mechanisms of Injury in HIV-Associated Nephropathy. Front Med (Lausanne). 2018; 5:177. PMID: 29930940 PMCID: PMC5999756</p>
<p><strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Coates PT. Using CRISPR to inactivate endogenous retroviruses in pigs: an important step toward safe xenotransplantation. Kidney Int. 2018; 93:4-6, PMID: 29198467.</p>
<p><strong><span style="text-decoration: underline;">Ross MJ.</span></strong> New Insights into APOL1 and Kidney Disease in African Children and Brazilians Living With End-Stage Kidney Disease. Kidney Int Rep. 2019; 4:908-910 PMC6611947.</p>
<p>Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Morlat P, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis. 2019 Oct 8;220(10):1629-1634. doi: 10.1093/infdis/jiz369. PubMed PMID: 31504669; PubMed Central PMCID: PMC6782100.</p>
<p>Gao X, Rosales A, Karttunen H, Bommana GM, Tandoh B, Yi Z, Habib Z, Agati V, Zhang W, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms. Sci Rep. 2019 Nov 1;9(1):15857. doi: 10.1038/s41598-019-52278-3. PubMed PMID: 31676833; PubMed Central PMCID: PMC6825220.</p>
<p>Townsend RR, Guarnieri P, Argyropoulos C, Blady S, Boustany-Kari CM, Devalaraja-Narashimha K, Morton L, Mottl AK, Patel U, Palmer M, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Sarov-Blat L, Steinbugler K, Susztak K. Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. Kidney Int. 2020 Jan;97(1):10-13. doi: 10.1016/j.kint.2019.09.020. PubMed PMID: 31901339.</p>
<div class="citation-text" data-citation-style="ama">Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, <strong><span style="text-decoration: underline;">Ross M,</span></strong> Forest S, Goldstein YD, Ajaimy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. Covid-19 and Kidney Transplantation. N Engl J Med. 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. Epub 2020 Apr 24. PMID: 32329975; PMCID: PMC7200055.</div>
<p>Dr. Michael Ross received his MD degree at NYU and completed internal medicine residency training at Duke University, followed by Nephrology Fellowship training at the Icahn School of Medicine at Mount Sinai. While he was on the faculty in the Mount Sinai Division of Nephrology from 2001-17, he served as Nephrology Fellowship Program Director from 2004-2015. He became Chief of Nephrology at the James J. Peters VA Medical Center from 2014-2017, where he helped establish the only VA Kidney Transplant Program in the northeastern US. Dr. Ross became Chief of the Division of Nephrology at the Albert Einstein College of Medicine/Montefiore Medical Center in 2017 where he is currently Chief of Nephrology and Professor of Medicine and Developmental and Molecular Biology. </p><p>Dr. Ross has served in several national/international leadership roles for the American Society of Nephrology and other organizations, served as Deputy Editor of Kidney International, and is currently Nephrology Section Editor of the American College of Physicians Medical Knowledge and Self-Assessment Program. Dr. Ross was also the recipient of the 2021 American Society of Nephrology Distinguished Leader Award. The major focus of Dr. Ross’ research program is to identify novel mechanisms of HIV-induced kidney diseases and other forms of kidney injury. He is also site principal investigator of clinical and translational research studies of diabetic kidney disease and other kidney diseases. <br /></p>
<p>My research interests are: Clostridium difficile, Tuberculosis, Molecular epidemiology, Molecular mechanisms of antibiotic resistance, Bacteriophage Therapy. </p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">Dr. Raff is a Professor of Medicine and the Associate Chair of Medicine for Undergraduate Medical Education. She has been the Course Director for the Einstein first year medical student Renal System Course since 2007 and the Internal Medicine Clerkship and Acting Internship Director since 2012.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;"> </p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">She a faculty mentor for the student led Step 1 Group near-peer evidence based guidance program and the Internal Medicine Interest Group.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"> </p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">She has a clinical practice of CKD and ESRD patients and enjoys rounding on the inpatient Renal Consult and Dialysis services.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"> </p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">Dr. Raff’s contributions in the field of Medical Education include serving as a Case Editor for Aquifer Internal Medicine, contributing author and reviewer for the Clerkship Directors in Internal Medicine (CDIM) curriculum revision and MKSAP 19 Nephrology section committee member.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;"> </p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">She has been recognized for her teaching excellence at Einstein with the Samuel M. Rosen Outstanding Teacher Award for Excellence in Basic Science Teaching, the Harry Eagle Award for Outstanding Basic Science Teaching, the Harry H. Gordon Award for Outstanding Clinical Teaching and membership in the Leo M. Davidoff Society.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;"> </p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">Dr. Raff received a bachelor's degree in biology from Indiana University and a MD from Albert Einstein College of Medicine. She completed a residency in Internal Medicine at NewYork Presbyterian Hospital and a chief resident year at NYU Downtown Hospital. She returned to Einstein/Montefiore for a Nephrology Fellowship and joined the Einstein Division of Nephrology faculty in 2004.</p>
Autosomal Dominant Polycystic Kidney Disease (ADPKD)<br />Chronic Kidney Disease (CKD)<br />End Stage Kidney Disease (ESKD, ESRD)<br />Acute Kidney Injury (AKI)<br />Glomerular diseases<br />Hypertension<br />Electrolyte Disorders<br />Kidney Stones<br />
<p><span style="color:black;"> </span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">1. </span><span style="font-size: 12pt; font-family: Cambria; color: #212121;">Fitz M, Adams W, Haist S, Hauer K, Ross P, <strong>Raff A</strong>, Agarwal G, Vu T, Appelbaum J, Lang V, Miller C, Grum C and the Clerkship Directors in Internal Medicine – National Board of Medical Examiners EXPRESS Study Group. Which Internal Medicine Clerkship Characteristics Are Associated With Students' Performance on the NBME Medicine Subject Exam? A Multi-Institutional Analysis. <em>Acad Med</em>. 2020;10.1097/ACM.0000000000003322 [published online ahead of print, 2020 Mar 17]. </span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria; color: #212121;">2. </span><span style="font-size: 12pt; font-family: Cambria;">Brien K (Author), Calvo L (Associate editor), <strong>Raff A</strong> (Case editor). <em>Aquifer Internal Medicine Case 33: 49-year-old woman with confusion</em>. 2019 </span><u><span style="font-size: 12pt; font-family: Cambria; color: #3366ff;">https://www.aquifer.org</span></u></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria; color: #212121;">3. </span><span style="font-size: 12pt; font-family: Cambria;">Khan M, Gil N, Lin W, Fiter R, Kenawy D, Burton W, <strong>Raff A</strong>. The impact of Step 1 scores on medical students’ residency specialty choice. <em>Med Sci Educ.</em> 28(4): 699-705. 2018.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">4. Ludwig A, <strong>Raff A</strong>, Lin J, Schoenbaum E. Group Observed Structured Encounter (GOSCE) for third year medical students improves self-assessment of clinical communication. <em>Medical Teacher</em> 39(9): 931-5. 2017.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">5. Golestaneh L, Neugarten J, Southern W, Kargoli F, <strong>Raff A</strong>. Improving the diagnostic workup of hyponatremia in the setting of kidney disease: a continuing medical education (CME) initiative. <em>Int Urol Nephrol</em> 49(3): 491-7. 2017</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">6. Czapka M, <strong>Raff A</strong>, Risley M. Safe Transitions: An active learning module for discharge summaries and interprofessional care. <em>MedEdPORTAL iCollaborative</em>. 2017</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">7. Tanenbaum, E, Johnson J, Jordan, E, Cottral J, Tenore C, Burton W, McGinn A<strong>, Raff A</strong>. An effective evidence-based student run near-peer support group for the USMLE Step 1 Exam. <em>Med Sci Educ</em>. 26(4): 691-9. 2016</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">8. Ludwig A, Lee R, Parish S, <strong>Raff A</strong>. Four-station group observed structured clinical encounter for formative assessment of communication skills for internal medicine clerks. <em>MedEdPORTAL Publications</em>. 12:10444. 2016 </span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">9. Chen W, Melamed M, Hostetter T, Bauer C, <strong>Raff A</strong>, Almudevar A, Lalonde A, Messing S, Abramowitz M. Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study. <em>BMC Nephrol</em>. 17(1): 114. doi: 10.1186/s12882-016-0331-6. 2016</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">10. Jion Y, <strong>Raff A</strong>, Grosberg B, Evans R. The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension. <em>Headache</em>. 55(1): 161-6. 2015</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">11. Jion Y, <strong>Raff A</strong>, Grosberg B, Evans R. Topiramate and nephrolithiasis: a response. <em>Headache</em>. 55(5): 710-2. 2015</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">12. Abramowitz, M, Melamed M, Bauer C, <strong>Raff A</strong>, Hostetter T. Effects of oral sodium bicarbonate in patients with CKD. <em>Clin J Am Soc Nephrol</em>. 8(5): 714-20. 2013</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">13. Berman N, Lectura M, Thurman J, Reinecke J, <strong>Raff A</strong>, Melamed M, Quan Z, Evans T, Meyer T, Hostetter T. A zebrafish model for uremic toxicity: role of the complement pathway. <em>Blood Purif</em>. 35(4): 265-9. 2013</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">14. Bomback A, <strong>Raff A</strong>. Olfactory function in dialysis patients: a potential key to understanding the uremic state. <em>Kidney Int</em>. 80(8): 803-5. 2011</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">15. Ponda M, Quan Z, Melamed M, <strong>Raff A</strong>, Meyer T, Hostetter T. Methylamine clearance by haemodialysis is low. <em>Nephrol Dial Transplant</em>. 25(5): 1608-13. 2010</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">16. <strong>Raff A</strong>, Lieu S, Melamed M, Quan Z, Ponda M, Meyer T, Hostetter T. Relationship of Impaired Olfactory Function in ESRD to Malnutrition and Retained Uremic Molecules. <em>Am J Kidney Dis</em>. 52(1): 102-10. 2008</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">17. <strong>Raff A</strong>, Meyer T, Hostetter T. New Insights into uremic toxicity. <em>Curr Opin Nephrol Hypertens</em>. 17(6): 560-5. 2008</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">18. Susztak K, <strong>Raff A</strong>, Schiffer M, Bottinger E. Glucose – induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. <em>Diabetes</em>. 55(1): 225-33. 2006</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">19. Schiffer M. Susztak K, Ranalletta M, <strong>Raff A</strong>, Bottinger E, Charron M. Localization of the GLUT8 transporter in murine kidney and regulation in vivo in non-diabetic and diabetic conditions. <em>Am J Physiol Renal Physiol</em>, 289(1): F186-193. 2005</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">20. <strong>Raff A</strong>, Hebert T, Pullman J, Coco M. Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted? <em>Clinical Nephrology</em>, 63(5): 375-380. 2005</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">21. Spector M, <strong>Raff A</strong>, DeSilva H, Lee K, Osley M. Hir1p and Hir2p function as transcriptional corepressors to regulate histone gene transcription in <em>Saccharomyces cerevisiae </em>cell cycle. <em> Molecular and Cellular Biology</em>, 17(2): 545-552. 1997</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">22. Recht J, Dunn B, <strong>Raff A</strong>, Osley M. Functional analysis of histone H2A and H2B in transcriptional repression in <em>Saccharomyces cerevisiae. Molecular and Cellular Biology</em>, 16(6): 2545-2553<em>.</em> 1996</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">23. Kopczynski J, <strong>Raff A</strong>, Bonner J. Translational readthrough at nonsense mutations in the <em>HSF1</em> gene of <em>Saccharomyces cerevisiae. </em> <em>Molecular and General Genetics</em>, 234: 369-378. 1992</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: 'Times New Roman';"> </span></p>
<p>Amanda C. Raff, MD, is Attending Physician, Professor and Associate Chair of Medicine for Undergraduate Medical Education at Montefiore-Einstein. She is also the co-director of the Montefiore-Einstein Autosomal Dominant Polycystic Kidney Disease Program. Dr. Raff’s clinical focus is on dialysis and the treatment of patients with chronic kidney disease and end stage kidney disease.</p><p>After earning her Bachelor of Science in biology at Indiana University, Dr. Raff completed her Doctor of Medicine at Albert Einstein College of Medicine, earning her degree in 1998. Her postdoctoral training began at New York Presbyterian Hospital with an internship and residency in internal medicine from 1998 through 2001. She was assistant chief resident at Memorial Sloan Kettering Cancer Center in 2000 and chief resident at New York University Downtown Hospital from 2001 to 2002. She then returned to Montefiore-Einstein to complete a two-year fellowship in nephrology in 2004.</p><p>Dr. Raff’s research focuses on medical education. She has been the Course Director for the Einstein medical student Renal Course since 2007 and the Internal Medicine Clerkship and Acting Internship Director since 2012. Dr. Raff’s contributions in the field of Medical Education include serving as a Nephrology section committee member for the American College of Physicians’ Medical Knowledge Self-Assessment Program (MKSAP) 19 and 20 as well as prior work as a Case Editor for Aquifer Internal Medicine and contributing author and reviewer for the Clerkship Directors in Internal Medicine (CDIM) curriculum revision.</p><p>An enthusiastic medical educator, Dr. Raff has received several awards for her teaching and in 2010 was inducted into the Leo M. Davidoff Society for outstanding achievement in the teaching of medical students. She is board certified and is a member the American Society of Nephrology and a fellow of the American College of Physicians.</p>